To the Editor: In their Editorial in response
to the article by Dr Lasser and colleagues,1
Drs Temple and Himmel2 of the FDA stated,
"it is incorrect to describe the introduction of unsafe drugs as frequent.
. . . " Nevertheless, they recommended that "a physician contemplating prescribing
a new drug should consider carefully the reason for the choice, particularly
when an equally effective alternative is available. . . . "2
Greene PJ, La Vaque TJ. Postmarketing Surveillance and Black Box Warnings. JAMA. 2002;288(8):955–959. doi:10.1001/jama.288.8.955
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: